ticlopidine has been researched along with Angina Pectoris, Stable in 25 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)." | 9.34 | Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020) |
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 9.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
"Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina." | 8.90 | Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
"To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)." | 7.81 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015) |
"Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 5.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)." | 5.34 | Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020) |
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 5.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
" Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
"Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina." | 4.90 | Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
"To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)." | 3.81 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015) |
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI." | 2.77 | Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012) |
"Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 1.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 24 (96.00) | 24.3611 |
2020's | 1 (4.00) | 2.80 |
Authors | Studies |
---|---|
Park, JH | 1 |
Kim, JS | 1 |
Ahn, CM | 1 |
Hong, SJ | 1 |
Ahn, KJ | 1 |
Choi, JW | 1 |
Joo, HJ | 1 |
Yu, CW | 1 |
Lim, DS | 1 |
Jiang, Z | 1 |
Wu, H | 1 |
Duan, Z | 1 |
Wang, Z | 1 |
Hu, K | 1 |
Ye, F | 1 |
Zhang, Z | 1 |
Phankingthongkum, R | 1 |
Panchavinnin, P | 1 |
Chinthammitr, Y | 1 |
Tresukosol, D | 1 |
Chotinaiwattarakul, C | 1 |
Tungsubutra, W | 1 |
Wongpraparut, N | 1 |
Kitrattana, B | 1 |
Leewanun, P | 1 |
Kim, HS | 1 |
Chang, K | 1 |
Koh, YS | 1 |
Park, MW | 1 |
Choi, YS | 1 |
Park, CS | 1 |
Oh, M | 1 |
Kim, EY | 1 |
Shon, JH | 1 |
Shin, JG | 1 |
Seung, KB | 1 |
Verdoia, M | 1 |
Schaffer, A | 1 |
Barbieri, L | 1 |
Cassetti, E | 1 |
Piccolo, R | 1 |
Galasso, G | 1 |
Marino, P | 1 |
Sinigaglia, F | 1 |
De Luca, G | 1 |
Woo, JS | 1 |
Kim, W | 1 |
Jang, HH | 1 |
Kim, JB | 1 |
Kim, WS | 1 |
Kim, KS | 1 |
Mizia-Stec, K | 3 |
Mizia, M | 2 |
Haberka, M | 3 |
Lasota, B | 3 |
Gieszczyk-Strózik, K | 1 |
Chmiel, A | 2 |
Najda, J | 2 |
Gąsior, Z | 3 |
Kyrcz-Krzemień, S | 3 |
Legrand, V | 2 |
Cuisset, T | 1 |
Chenu, P | 2 |
Vrolix, M | 2 |
Martinez, C | 1 |
Dens, J | 1 |
Gach, O | 1 |
Boland, J | 1 |
Claeys, MJ | 1 |
Magne, J | 2 |
Barbato, E | 2 |
Wijns, W | 2 |
Arima, Y | 1 |
Hokimoto, S | 1 |
Akasaka, T | 1 |
Mizobe, K | 1 |
Kaikita, K | 1 |
Oniki, K | 1 |
Nakagawa, K | 1 |
Ogawa, H | 1 |
Paarup Dridi, N | 1 |
Johansson, PI | 1 |
Lønborg, JT | 1 |
Clemmensen, P | 1 |
Radu, MD | 1 |
Qayyum, A | 1 |
Pedersen, F | 1 |
Kollslid, R | 1 |
Helqvist, S | 1 |
Saunamäki, K | 2 |
Kelbæk, H | 2 |
Jørgensen, E | 1 |
Engstrøm, T | 1 |
Holmvang, L | 1 |
Rossini, R | 1 |
Musumeci, G | 1 |
Capodanno, D | 1 |
Lettieri, C | 1 |
Limbruno, U | 1 |
Tarantini, G | 1 |
Russo, N | 1 |
Calabria, P | 1 |
Romano, M | 1 |
Inashvili, A | 1 |
Sirbu, V | 1 |
Guagliumi, G | 1 |
Valsecchi, O | 1 |
Senni, M | 1 |
Gavazzi, A | 1 |
Angiolillo, DJ | 1 |
Kristensen, SL | 1 |
Galløe, AM | 1 |
Thuesen, L | 1 |
Thayssen, P | 1 |
Havndrup, O | 1 |
Hansen, PR | 1 |
Bligaard, N | 1 |
Junker, A | 1 |
Aarøe, J | 1 |
Abildgaard, U | 1 |
Jeppesen, JL | 1 |
Konishi, A | 1 |
Shinke, T | 1 |
Otake, H | 1 |
Takaya, T | 1 |
Osue, T | 1 |
Kinutani, H | 1 |
Kuroda, M | 1 |
Takahashi, H | 1 |
Terashita, D | 1 |
Hirata, K | 1 |
Ako, J | 1 |
Morino, Y | 1 |
Okuizumi, K | 1 |
Usami, M | 1 |
Nakamura, M | 2 |
Legrand, D | 1 |
Abtan, J | 1 |
Steg, PG | 1 |
Stone, GW | 1 |
Mahaffey, KW | 1 |
Gibson, CM | 1 |
Hamm, CW | 1 |
Price, MJ | 1 |
Abnousi, F | 1 |
Prats, J | 1 |
Deliargyris, EN | 1 |
White, HD | 1 |
Harrington, RA | 1 |
Bhatt, DL | 1 |
Stefanescu Schmidt, AC | 1 |
Kereiakes, DJ | 1 |
Cutlip, DE | 1 |
Yeh, RW | 1 |
D'Agostino, RB | 1 |
Massaro, JM | 1 |
Hsieh, WH | 1 |
Mauri, L | 1 |
Aradi, D | 1 |
Rideg, O | 1 |
Vorobcsuk, A | 1 |
Magyarlaki, T | 1 |
Magyari, B | 1 |
Kónyi, A | 1 |
Pintér, T | 1 |
Horváth, IG | 1 |
Komócsi, A | 1 |
Motoda, C | 1 |
Ueda, H | 1 |
Hayashi, Y | 1 |
Toyofuku, M | 1 |
Okimoto, T | 1 |
Otsuka, M | 1 |
Tamekiyo, H | 1 |
Kawase, T | 1 |
Kihara, Y | 1 |
Volpi, E | 1 |
Giusti, L | 1 |
Ciregia, F | 1 |
Da Valle, Y | 1 |
Giannaccini, G | 1 |
Berti, S | 1 |
Clerico, A | 1 |
Lucacchini, A | 1 |
Kunecki, M | 1 |
Gieszczyk, K | 1 |
Isshiki, T | 1 |
Kimura, T | 1 |
Ueno, T | 1 |
Igarashi, K | 1 |
Yokoi, H | 1 |
Kobayashi, M | 1 |
Ikari, Y | 1 |
Viswanathan, GN | 1 |
Marshall, SM | 1 |
Schechter, CB | 1 |
Balasubramaniam, K | 1 |
Badimon, JJ | 1 |
Zaman, AG | 1 |
Shetty, RK | 1 |
Madken, M | 1 |
Naha, K | 1 |
Vivek, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)[NCT01239914] | 11,719 participants (Actual) | Observational | 2005-01-31 | Completed | |||
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention[NCT00638326] | Phase 3 | 500 participants (Anticipated) | Interventional | 2008-03-31 | Terminated (stopped due to Greater differences between randomized patients than previously anticipated) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) |
---|---|
Cangrelor Treatment Arm | 257 |
Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
Intervention | participants (Number) | |||
---|---|---|---|---|
Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
Propensity-matched DES | 1.70 |
Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 0.50 |
BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 0.50 |
BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 0.69 |
DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 0.40 |
DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
BMS 30-month DAPT | 2.03 |
BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
BMS 30-month DAPT | 2.09 |
BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
DES 30-month DAPT | 2.74 |
DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
DES 30-month DAPT | 2.53 |
DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
Intervention | percentage of patients (Number) |
---|---|
Propensity-matched DES | 11.37 |
Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 4.04 |
BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
BMS 30-month DAPT | 4.68 |
BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 5.62 |
DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
Intervention | percentage of patients (KM estimate) (Number) |
---|---|
DES 30-month DAPT | 4.34 |
DES 12-month DAPT | 5.92 |
1 review available for ticlopidine and Angina Pectoris, Stable
Article | Year |
---|---|
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angina, Stable; Case Management; Clopidogrel; Endpoi | 2014 |
13 trials available for ticlopidine and Angina Pectoris, Stable
Article | Year |
---|---|
Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven
Topics: Angina, Stable; Clopidogrel; Coronary Angiography; Humans; Myocardial Infarction; Percutaneous Coron | 2020 |
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Topics: Adult; Aged; Alleles; Angina, Stable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C | 2013 |
N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Docosahexaenoic Acids; Drug Combination | 2013 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
The STIB score: a simple clinical test to predict clopidogrel resistance.
Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Belgium; Biomarkers; Blood Platelets; Body Mas | 2015 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo | 2016 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
Topics: Aged; Angina, Stable; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relations | 2012 |
Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angina, Stable; Aspirin; Drug-Eluting Stents; Female | 2012 |
Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Blood Platelets; Blotting, Western; Clopidogre | 2012 |
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
11 other studies available for ticlopidine and Angina Pectoris, Stable
Article | Year |
---|---|
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control | 2013 |
High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Humans; Male; | 2013 |
Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy.
Topics: Aged; Angina, Stable; Blood Platelets; Brachial Artery; Cell Count; Clopidogrel; Endothelium, Vascul | 2014 |
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytoc | 2015 |
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Stable; Clopidogrel; Female; Humans; Male; Percutaneous Coronary In | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.
Topics: Aged; Angina, Stable; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; H | 2014 |
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous | 2015 |
Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Drug Therapy, Com | 2016 |
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female; | 2016 |
Leucocytoclastic vasculitis as a late complication of clopidogrel therapy.
Topics: Angina, Stable; Biopsy; Clopidogrel; Female; Follow-Up Studies; Humans; Middle Aged; Purinergic P2Y | 2013 |